Objective Although the major cause of morbidity and mortality in patients with diabetes mellitus (DM) is cardiovascular disease, DM is also associated with certain site-specific cancers. However, whether DM is associated with an increased risk of cancer of the digestive tract remains undetermined. A nationwide, population-based database in Taiwan was analyzed to explore the relationship between DM and cancer of the digestive organs. Methods From 2000 to 2007, a study cohort consisting of 39,515 patients with newly diagnosed diabetes without a previous diagnosis of gastrointestinal (GI) cancer was identified from the National Health Insurance Research Database in Taiwan. A control cohort of 79,030 age-and sex-matched non-diabetic subjects was selected to compare the occurrence of GI malignancies between the two groups. The association between the incidence of GI cancers and the use of glucose-lowering therapies was also investigated. Results During the 7-year follow-up period, GI cancers developed in 929 diabetic patients (2.35%) and 1,126 subjects (1.42%) in the comparison cohort. DM was associated with a 2.75-fold (95% confidence interval (CI), 2.51-3.02) higher risk of developing GI malignancy. Among GI cancers, the incidences of stomach (adjusted hazard ratio (HR), 1.49; 95% CI, 1.16-1.92), liver (adjusted HR, 2.65; 95% CI, 2.29-3.07), colon (adjusted HR, 1.58; 95% CI, 1.28-1.94) and pancreatic cancers (adjusted HR, 4.35; 95% CI, 2.93-6.47) were significantly increased in the patients with DM. An analysis of the effects of various glucose-lowering therapies in the diabetic patients revealed the use of α-glucosidase inhibitors to be associated with a lower risk of hepatic cancer (adjusted HR, 0.62; 95% CI, 0.4-0.94). Thiazolidinedione (TZD) treatment was associated with lower stomach (adjusted HR, 0.11; 95% CI, 0.02-0.82) and hepatic cancer risks (adjusted HR, 0.46; 95% CI, 0.29-0.73), while sulfonylurea use was associated with a lower colon cancer risk (adjusted HR, 0.74; 95% CI, 0.51-1.09) and a higher pancreatic cancer risk (adjusted HR, 2.36; 95% CI, 1.21-4.61). Conclusion Patients with DM have an increased risk of GI malignancy that may be affected by the use of different categories of glucose-lowering therapies.
Introduction
The prevalence of diabetes mellitus (DM) is rapidly increasing globally and has become a major worldwide public health problem (1) . The World Health Organization has estimated that the number of diabetic patients worldwide will double within the next 10 years, from approximately 150 million in 2000 to 300 million in 2025 (2) . Although the major cause of morbidity and mortality in diabetic patients is cardiovascular disease, DM is also associated with certain site-specific cancers, most notably colorectal, liver, pancreatic and endometrial cancers (3) (4) (5) (6) (7) (8) (9) (10) (11) .
DM and cancer share many risk factors, including aging, obesity, diet and physical inactivity (6) . However, the potential biological links between the two diseases are not well understood. Evidence from observational studies suggests that certain glucose-lowering therapies are associated with increased or reduced risks of cancer (6, (12) (13) (14) (15) (16) (17) (18) (19) . Although previous research studies have revealed the linkages between DM and colorectal, liver and pancreatic cancers (7) (8) (9) 11) , the associations between DM and other types of gastrointestinal (GI) cancers have not been well studied and the evidence is inconclusive. In the present study, we aimed to compare the differences in GI cancer occurrence between diabetic patients and a non-diabetic cohort using a population-based cohort database in Taiwan. Furthermore, we investigated the associations between GI cancer risk and various glucose-lowering therapies in diabetic patients.
Materials and Methods

Database
The National Health Insurance program in Taiwan has been in operation since 1995. It enrolls nearly all of the inhabitants of Taiwan (21, 869 ,478 beneficiaries out of 22,520,776 inhabitants as of the end of 2002) (20) . Currently, the National Health Insurance Research Database (NHIRD) at the National Health Research Institute (NHRI) in Miaoli (Taiwan) is responsible for maintaining the complete National Health Insurance claims database and has published several dozen extracted datasets for researchers (21) (22) (23) (24) .
This study used a cohort dataset consisting of 1,000,000 randomly sampled people and collected all records on these individuals. These random samples were confirmed by the NHRI to be representative of the Taiwanese population. In these datasets, each patient's original identification number was encrypted to protect their privacy. In addition, the encrypting procedure was consistent, so that linking claims belonging to the same patient is feasible within the NHIRD. This study was exempt from full review by the Institutional Review Board of Taipei Veterans General Hospital since the dataset used consisted of de-identified secondary data released to the public for research purposes.
Study sample
We identified 39,515 diabetic patients who received either ambulatory care visits or hospitalization for treatment of DM (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 250.xx). The first and last outpatient visits for DM were required to be 30 days apart to avoid accidental inclusion of miscoded patients. A control group was selected from non-diabetic subjects in the database. The subjects were matched for age, sex and the enrollment date using stratified random sampling, which has been applied in our previous studies (22, 24) . In order to observe the risk of developing malignancy in DM patients, subjects who had already been diagnosed as having any type of malignancy (ICD-9-CM codes 140.xx to 239.xx) before enrollment were excluded from this study. Medical comorbidities such as coronary artery disease (CAD; ICD-9-CM codes 410.xx to 414.xx), arrhythmia (ICD-9-CM codes 427.xx), hyperlipidemia (ICD-9-CM, Clinical Modification codes 272.xx), congestive heart failure (CHF; ICD-9-CM codes 428.xx), valvular heart disease (VHD; ICD-9-CM codes 394.xx to 397.xx) and ischemic stroke (ICD-9-CM codes 434.xx to 437.1) were selected. The diagnosis of GI cancer was primarily confirmed based on the results of the pathological findings for insurance purposes (ICD-9-CM codes 150.xx to 159.xx). Confirming a diagnosis of cancer using insurance claims is valid and has been used in our previous study (23) . In order to further investigate the effects of hypoglycemic therapy for diabetes on the GI cancer risk, medications, including α-glucosidase inhibitors, biguanides, insulin, sulfonylureas, non-sulfonylurea insulin secretory analogues (meglitinides) and thiazolidinedione (TZD), were analyzed in a subsequent Cox regression model. The hypoglycemic therapy subscription data were analyzed before the primary endpoint.
Statistical analysis
The Microsoft SQL Server 2005 software program was used for data management and computing. The statistical analysis was performed using the SPSS software package (Version 15.0, SPSS Inc., Chicago, Illinois, USA). All data were expressed as the frequency (percentage) for ordinal and categorical data or the mean ± standard deviation (SD) for continuous data. Continuous data were compared between the study group and the comparison group using Student's ttest. Categorical data were compared using the Chi-square test and Yates' correction or Fisher's exact test as appropriate. A univariate regression analysis was carried out using a Cox proportional hazards regression analysis. The Cox analyses were censored at death, the occurrence of an event (cancer development) or the final follow-up among the alive subjects without events. Statistical significance was inferred at a two-sided p value of <0.05. 
Results
The distributions of demographic characteristics and selected comorbid medical disorders in the two cohorts are presented in Table 1 . The mean age of the patients with DM was 58.52±14.9 years. Approximately half (55.93%) of the patients examined were men, and the prevalence of comorbidities such as a history of CAD, cardiac arrhythmia, CHF, VHD, hyperlipidemia and ischemic stroke was significantly higher in the DM group. Over a 7-year follow-up period, 2,055 subjects (1.7%) developed GI malignancies, including 929 diabetic patients (2.35%) and 1,126 subjects (1.42%) in the comparison cohort (p<0.001). The patients with DM had a higher incidence of malignancies of the stomach (0.27% vs. 0.21%, p=0.044), liver (1.06% vs. 0.49%, p<0.001), pancreas (0.22% vs. 0.06%, p<0.001) and colon (0.4% vs. 0.32%, p=0.02) than the controls (Table 2) . After adjusting for age, sex and selected comorbidities, DM was found to be significantly associated with increased risks of malignancies of the stomach (1.49; 95% confidence interval (CI), 1.16-1.92), liver (2.65; 95% CI, 2.29-3.07), colon (1.58; 95% CI, 1.28-1.94), pancreas (4.35; 95% CI, 2.93-6.47) and total GI malignancy occurrence (2.75; 95% CI, 2.51-3.02) (Figure) , thus indicating that DM is an independent factor associated with the future risk of GI cancer development.
Although DM was found to be associated with an increased risk of GI malignancy, whether glucose-lowering therapies for DM modulate the risk of GI cancer among diabetic patients remained undetermined. Table 3 shows the hazard ratios between various cancers of the GI tract and different types of glucose-lowering therapies. The adjusted hazard ratio (HR) for liver cancer in α-glucosidase inhibitortreated patients was 0.62 (95% CI, 0.4-0.94) after adjustment for sex, age and selected comorbidities. In the TZDtreated patients, decreased risks of stomach (adjusted HR, 0.11; 95% CI, 0.02-0.82) and liver cancers (0.46; 95% CI, 0.29-0.73) were observed. Furthermore, sulfonylurea treatment was found to be correlated with an increased pancreatic cancer risk (adjusted HR, 2.36; 95% CI, 1.21-4.61) and decreased gallbladder and extrahepatic duct cancer risks (0.36; 95% CI, 0.14-0.92). No significant differences in overall GI cancer risk were detected between the patients treated with biguanides, insulin or nonsulfonylurea insulin secretory analogues.
Discussion
Although increased risks of pancreatic, colorectal and liver cancer have been reported in diabetic patients (4, 7, 8, 10, 11) , the associations between DM and other types of GI malignancies have not yet been studied in detail, especially among Asian populations. In the present study, the risk of developing cancers of the stomach, liver, colon or pancreas was higher in the diabetic patients than in the age-and sexmatched non-exposure controls. Furthermore, a subsequent Cox regression analysis of the various glucose-lowering therapies used in the diabetic patients demonstrated that the use of α-glucosidase inhibitors is associated with a lower risk of hepatic cancer, the use of TZD is associated with decreased risks of stomach and hepatic cancer and the use of sulfonylureas is associated with a lower risk of colon cancer and a higher risk of pancreatic cancer.
Type 2 DM and central obesity with insulin resistance have been reported to be associated with an increased risk of certain types of cancer. Previous meta-analyses have demonstrated that DM is associated with increased risks of breast, colon and pancreatic cancers (4, 10, 25, 26) . Furthermore, a recent German cohort study identified an excess overall cancer risk among diabetic patients, with an odds ratio for all cancers of 1.64 in comparison with the control group (27) . A large hospital discharge database study of American veterans reported that diabetic patients have a 3-fold higher risk of developing pancreatic cancer and a 2-fold higher risk of developing biliary cancer than non-DM patients (28). However, previous reports on the association be- 49; 95% confidence interval (CI), 1.16-1.92), liver (2.65; 95% CI, 2.29-3.07), colon (1.58; 95% CI,  1.28-1.93) and pancreas (p<0.001) . GI: gastrointestinal, GB: gallbladder tween DM and cancer are inconsistent, and further largescale population-based studies are needed to confirm this association. In vivo models showing reduced tumor growth in the setting of type 1 DM suggest that hyperglycemia does not lead to increased neoplastic growth, at least in the presence of insulin deficiency (29) . Therefore, the use of nationwide population-based datasets linked to the NHIRD should reduce selection and nonresponse biases and provide useful information to clarify the relationship between DM and cancer risk. In the present study, a large sample size provided adequate statistical power to detect differences in the risk of cancer between patients with and without DM.
The present analysis of GI system cancers demonstrated an association between DM and increased risks of gastric, hepatic, colon and pancreatic cancers using a large national insurance database in Taiwan. The present results confirm the findings of previous studies showing an association between DM and a higher risk of cancer and extend this association to GI tract malignancies. The biological mechanisms underlying the association between DM and cancer tend to be site-specific. Elevated levels of IGF-1, which is a common finding in DM patients, are the result of reduced insulin sensitivity and compensatory hyperinsulinemia. This may in turn stimulate cell proliferation primarily in the liver, pancreas, colon, prostate and ovaries (30, 31) . Helicobacter pylori gastritis enhances glucose and meal-stimulated insulin release, most likely by increasing gastrin secretion. The resulting hyperinsulinemia increases reactive oxygen-related damage to DNA and may induce genetic or epigenetic alterations in the gastric mucosa, which can play an important role in gastric carcinogenesis (32) . The incidence of Helicobacter pylori gastritis was high among the DM patients investigated in a Chinese epidemiology study (33) . An experimental study showed that hepatitis C virus infection itself can induce insulin resistance via the actions of hepatitis C virus core proteins in disturbing the insulin intracellular signaling pathway, which may be the initial step in the cascade of carcinogenesis (34) .
Carcinogenesis is a complex process, and the mechanisms underlying the process of carcinogenesis in patients with DM are not well understood. Possible mechanisms include hyperinsulinemia (either endogenous due to insulin resistance or exogenous due to administered insulin or insulin secretogogues), hyperglycemia and chronic inflammation (6) . Insulin stimulates cell growth (35) , and most cancer cells express excess insulin-like growth factor (IGF) receptors (36), thus suggesting that hyperinsulinemia, which is usually associated with DM, may contribute to the malignant phenotype. In addition, hyperglycemia enhances responsiveness to IGF-I, which causes increased vascular smooth muscle cell proliferation and migration (37) . An increased metabolic rate is also associated with most cancers, and hyperglycemia is considered to be a risk factor for carcinogenesis. Specific antidiabetic drugs have been suggested to increase or decrease the risk of cancer in patients with DM (19) . The use of the long-acting insulin analog glargine is suspected to be associated with an increased risk of cancer (15) , whereas metformin treatment has been reported to be correlated with a decreased cancer risk (12, (38) (39) (40) . Metformin may protect against carcinogenesis by stimulating peripheral AMP-activated protein kinase (AMPK) with reduced hepatic gluconeogenesis and insulin sensitivity in muscle (39) (40) (41) . The present results show that α-glucosidase inhibitors are associated with a lower risk of hepatic cancer, whereas TZD is associated with lower stomach and hepatic cancer risks. Sulfonylurea use, on the other hand, is associated with a lower risk of colon cancer and a higher risk of pancreatic cancer. Although the exact mechanisms underlying these effects remain undetermined, our results support the existence of an association between hypoglycemic agents and cancer development. α-glucosidase inhibitors have been reported to exert prolonged antiviral effects against the hepatitis B virus, which is the major risk factor for hepatic cancer. Galli et al. demonstrated that TZD may inhibit hepatocarcinogenesis (42) . The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand has been reported to inhibit colon cancer cell proliferation in vitro (43); however, TZD did Table 3 not decrease the risk of colon cancer in our study. Sulfonylurea derivatives have been reported to induce apoptosis in human colon cancer cells in vitro (44) . In summary, evidence for the effects of specific drugs on cancer risk is limited, and further prospective research is needed to clarify these issues in order to understand the links between DM, antidiabetic drugs and malignancy. Our study is a large population-based epidemiological study that was conducted to investigate the association between DM and the occurrence of GI cancer. The strength of our study lies in the use of a population-based dataset, which enrolled a large sample of subjects, enabling us to prospectively trace the differences between the two groups. However, there remain some limitations that are associated with our study. First, certain confounders such as environmental exposure and family history background were unavailable due to the limitations of the NHI database. Personal information, such as body weight, diet, alcohol consumption and genetic variables, were also not available due to the privacy policy governing this database. Second, the diagnosis of DM (250.XX) and cancer was based on the administrative claims data reported by physicians and hospitals. Type 1 or type 2 DM were not differentiated in the current study. Finally, more than 98% of the residents of Taiwan are of Chinese ethnicity. The ability to generalize the results to other racial/ethnic groups is unclear. Further studies are therefore needed to confirm our findings and their relevance in relation to other ethnic groups.
Conclusion
The analysis of a large cohort of diabetic patients over a 7-year period in Taiwan revealed a significantly increased risk of GI malignancy in this population. The risk of cancer in DM patients may be affected by the use of antidiabetic drugs, and further investigation is required owing to the limited clinical data currently available. In addition to vascular disease, DM is associated with premature death from several cancers (45) . The early detection of GI malignancy using appropriate screening methods should therefore be an important component of the clinical management of DM patients. Elucidating the detailed biological mechanisms underlying the association between DM and GI malignancy requires further studies and may help to reduce both the mortality and morbidity observed in these patients.
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